Artificial intelligence company, BenevolentAI and a collection of UK sight loss charities are working together to find treatments and a potential cure for age-related macular degeneration (AMD).
BenevolentAI is working with Action Against AMD to use its technology to potentially cure what it is the leading cause for blindness in the UK.
Action for AMD has been formed by Blind Veterans UK, Fight for Sight, the Macular Society and Scottish War Blinded and will increase funding for research into the condition.
BenevolentAI will use its technology platform to review and analyse millions of scientific papers, clinical trials, information formulas, patents and additional data sets relating to AMD. The technology will then conduct complex reasoning to create a new understanding of AMD, learn, explore, create and translate what it has learnt from the information. The process could potentially highlight important research areas and find possible ways of treating and preventing AMD.
The disease is the main cause of sight loss in developed countries and the third biggest worldwide. More than 600,000 people have late stage AMD in the UK, a number which is expected to double by 2050.
Dr Jackie Hunter, CEO BenevolentBio, the bioscience subsidiary of BenevolentAI said: “BenevolentAI’s deep learning linguistic models, knowledge graph and algorithms will be applied to create a better understanding of AMD, generate new insights and identify promising new research areas for treating this devastating condition.”
Action Against AMD chair, Rob Bryan said: “AI offers an exciting new way to approach medical research. We must find new treatments for AMD because it will affect tens of millions of older people across the world in the coming decades. We are delighted to be collaborating with BAI on this ground-breaking project.”
“BenevolentAI accelerates scientific discovery to tackle some of the largest and most pressing challenges in medicine. AMD is one such challenge. We are delighted to partner with AAA to generate new ideas in AMD that have the potential to deliver new medicines to a vast number patients.” Dr Hunter concluded.